{"title":"急性心肌梗死后心源性休克的临床回顾--血管重建、机械循环支持及其他。","authors":"Yuichi Saito, Kazuya Tateishi, Yoshio Kobayashi","doi":"10.1253/circrep.CR-24-0141","DOIUrl":null,"url":null,"abstract":"<p><p>Owing to recent advances in early reperfusion and pharmacological therapies, the prognosis of patients with acute myocardial infarction (AMI) has considerably improved over the past decades. However, the mortality rate remains high at ~40-50% after AMI when complicated by cardiogenic shock. Although immediate coronary revascularization of the infarct-related artery has been the only evidence-based treatment, temporary mechanical circulatory support with a microaxial flow pump (Impella) has become another therapeutic option supported by randomized trial data in highly selected patients. Here we summarize the latest evidence concerning clinical challenges in patients with AMI and cardiogenic shock.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 1","pages":"6-14"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711789/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical Review of Cardiogenic Shock After Acute Myocardial Infarction - Revascularization, Mechanical Circulatory Support, and Beyond.\",\"authors\":\"Yuichi Saito, Kazuya Tateishi, Yoshio Kobayashi\",\"doi\":\"10.1253/circrep.CR-24-0141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Owing to recent advances in early reperfusion and pharmacological therapies, the prognosis of patients with acute myocardial infarction (AMI) has considerably improved over the past decades. However, the mortality rate remains high at ~40-50% after AMI when complicated by cardiogenic shock. Although immediate coronary revascularization of the infarct-related artery has been the only evidence-based treatment, temporary mechanical circulatory support with a microaxial flow pump (Impella) has become another therapeutic option supported by randomized trial data in highly selected patients. Here we summarize the latest evidence concerning clinical challenges in patients with AMI and cardiogenic shock.</p>\",\"PeriodicalId\":94305,\"journal\":{\"name\":\"Circulation reports\",\"volume\":\"7 1\",\"pages\":\"6-14\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711789/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Circulation reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1253/circrep.CR-24-0141\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/10 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1253/circrep.CR-24-0141","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/10 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical Review of Cardiogenic Shock After Acute Myocardial Infarction - Revascularization, Mechanical Circulatory Support, and Beyond.
Owing to recent advances in early reperfusion and pharmacological therapies, the prognosis of patients with acute myocardial infarction (AMI) has considerably improved over the past decades. However, the mortality rate remains high at ~40-50% after AMI when complicated by cardiogenic shock. Although immediate coronary revascularization of the infarct-related artery has been the only evidence-based treatment, temporary mechanical circulatory support with a microaxial flow pump (Impella) has become another therapeutic option supported by randomized trial data in highly selected patients. Here we summarize the latest evidence concerning clinical challenges in patients with AMI and cardiogenic shock.